Proportions of participants achieving ADA targets by attainment of FPG and PPG targets at Week 30 in LixiLan-O and LixiLan-L trials. 1 Figure S2 Mean change in HbA1c and proportion of participants achieving HbA1c targets by attainment of FPG and PPG targets (AACE recommendations) at Week 30 in LixiLan-O and LixiLan-L trials. 2 Figure S3 Mean HbA1c by attainment of FPG and PPG targets (ADA and AACE recommendations) at Week 30 in LixiLan-O and LixiLan-L trials, respectively. 3 Figure S4 Mean basal insulin dose at Week 30 by attainment of FPG and PPG targets (ADA and AACE recommendations) at Week 30 in LixiLan-O and LixiLan-L trials. 4 Figure S5 Weight change by attainment of FPG and PPG targets (AACE recommendations) at Week 30 in LixiLan-O and LixiLan-L trials. 5 Figure S6 Proportions of participants achieving weight loss and mean weight by attainment of FPG and PPG targets (ADA and AACE recommendations) at Week 30 in LixiLan-O and LixiLan-L trials.
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Figure S1
Proportions of participants achieving ADA targets by attainment of FPG and PPG targets at Week 30 in LixiLan-O and LixiLan-L trials. 
Figure S6
Proportions of participants achieving weight loss and mean weight by attainment of FPG and PPG targets (ADA and AACE recommendations) at Week 30 in LixiLan-O and LixiLan-L trials.
6-7
Figure S7
Proportion of participants achieving composite endpoint of target HbA1c <53mmol/mol (<7.0%) without hypoglycaemia and without weight gain by attainment of FPG and PPG targets (AACE recommendations) at Week 30 in LixiLan-O and LixiLan-L trials.
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Figure S8
Number of people with Type 2 diabetes experiencing GI AEs by attainment of FPG and PPG targets (ADA and AACE recommendations, respectively) at Week 30 in LixiLan-O and LixiLan-L trials.
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Table S1
Participant demographic and baseline characteristics by attainment of FPG and PPG targets (AACE recommendations) in LixiLan-O.
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Table S2
Participant demographic and baseline characteristics by attainment of FPG and PPG targets (AACE recommendations) in LixiLan-L. If no assessment was available at Week 30, it was treated as not at goal. Significant P-values shown in bold. P-values for hypo incidence were from a generalized linear model (PROC GENMOD, Binomial distribution) which included treatment arm as factor P-values for hypo event were from a generalized linear model (PROC GENMOD, Negative Binomial distribution) which included treatment arm as factor, and log of exposure as offset term Hypoglycaemia events with missing 2-hr PPG are excluded. AACE, American Association of Clinical Endocrinologists; ADA, American Diabetes Association; FPG, fasting plasma glucose; iGlar, insulin glargine; iGlarLixi, insulin glargine + lixisenatide; PPG, postprandial plasma glucose; ptyear, patient-year; SE, standard error.
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